Table 1. Haemodynamic and laboratory analyses of ISCLS patients admitted to ICU because of shock.
| Variable | Acute phase | Post-acute phase | Recovery phase | p |
|---|---|---|---|---|
| Haemodynamics | ||||
| HR, mean (range), bpm | 125.7 (94.5–146.9) | 96.8 (90–105)* | 74 (67.7–85.8)* | <0.001 |
| SAP, mean (range), mmHg | 75.4 (55–96.1) | 109.2 (94.9–119.9)* | 122.6 (102.7–149)* | <0.001 |
| DAP, mean (range), mmHg | 50.7 (40–60.8) | 70 (60.3–77.4)* | 72.6 (56.3–90.5)* | 0.008 |
| Blood analysis | ||||
| Hb, mean (range), g/dL | 19.8 (12.1–24.7) | 16.8 (9.8–20.1) | 10.6 (7.7–13.4)*§ | 0.002 |
| Ht, mean (range), % | 57.2 (35.3–72) | 48.9 (27.9–57) | 31.1 (23–40)*§ | 0.002 |
| RBC, mean (range), 103 cells/mm3 | 6815 (4090–7990) | 5845 (3510–7070) | 3675 (2750–4700)*§ | 0.002 |
| WBC, mean (range), cells/mm3 | 38878 (18520–66440) | 23817 (6250–42470) | 10300 (7520–13840)* | 0.009 |
| PLT, mean (range), 103 platelets/mm3 | 223.6 (164–294) | 254.5 (159–353) | 173.1 (94–336) | 0.14 |
| PTT, mean (range), INR | 1.56 (0.97–2.36) | 1.2 (0.9–1.6) | 1.02 (0.77–1.15)* | 0.03 |
| PT, mean (range), INR | 1.56 (1.19–2.16) | 1.22 (1.1–1.44) | 1.1 (1.04–1.2)* | 0.08 |
| D-dimer, mean (range), μg/L | 1354 (503–3609) | 1243 (789–1770) | 827 (388–1065) | 0.64 |
| Urea, mean (range), mg/dL | 86 (67–116) | 144 (86–303) | 99.8 (36–172) | 0.3 |
| Creatinine, mean (range), mg/dL | 3.18 (2.2–4.3) | 3.8 (1.9–5.7) | 2.1 (1.03–4.3) | 0.06 |
| Albumin, mean (range), g/dL | 1.9 (0.9–2.5) | 2.8 (2.1–3.5) | 3.2 (2.7–3.7)* | 0.008 |
| C-reactive protein, mean (range), mg/L | 43 (7–88) | 44.5 (17–111) | 35.3 (8.9–67) | 0.86 |
| CPK, mean (range), U/L | 285 (129–540) | 1806 (118–9084) | 113 (28–206) | 0.1 |
| Lactate, mean (range), mmol/L | 4.2 (2.2–8.1) | 1.8 (0.9–2.8) | 0.8 (0.5–1)* | 0.003 |
Haemodynamic data, blood sample analyses and acid-base status of patients admitted to ICU because of life-threatening ISCLS attacks. HR, heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure. Values are shown as mean (range).
*p<0.05 with respect to the acute phase.
§p<0.05 with respect to the post-acute phase.